Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
Want to see KLRS full AI Analyst Report?
KLRS Stock Chart & Stats
$6.32
--
Market closed
$6.32
--
Day’s Range― - ―
52-Week Range$2.14 - $11.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)136.22K
Market Cap
$103.03M
Enterprise Value$52.08M
Total Cash (Recent Filing)$97.22M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 19, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding23,792,278
10 Day Avg. Volume189,046
30 Day Avg. Volume136,224
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.60K
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$15.75Price Target Upside149.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway / FinancingA funded runway into Q4 2027 and an oversubscribed $50M placement provide multi-year capital to advance TH103 toward Phase 3. This reduces near-term refinancing risk, enabling execution on clinical milestones that materially de-risk value creation over the next 2–3 years.
Low Financial LeverageMinimal debt relative to equity gives the company financial flexibility and lowers bankruptcy risk while it pursues costly clinical development. Low leverage preserves optionality for strategic capital raises or partnerships without constraining cash flow with high fixed interest obligations.
Governance ContinuityRe-election of directors, approval of governance actions, and auditor continuity indicate shareholder support and stable oversight. Strong governance continuity supports consistent clinical strategy execution and credibility with investors and partners through lengthy development cycles.
Bears Say
Pre-revenue Cash BurnZero product revenue combined with sustained operating cash burn requires ongoing external financing to fund R&D. Persistent large negative cash flow increases dilution risk and creates execution pressure if capital markets tighten, challenging long-term program advancement.
Equity Erosion / Negative ROEDeclining equity and strongly negative ROE reflect value erosion from recurring losses. This weakens the balance-sheet buffer against setbacks and can reduce strategic flexibility, making future financing more dilutive or costly and impairing long-term shareholder returns.
Clinical And Execution RiskAdvancing TH103 into later-stage trials carries inherent clinical, regulatory, and execution risk; failure or delays would materially impair prospects. Reliance on a single lead program concentrates risk and extends time to potential revenue, heightening binary outcome exposure.
Kalaris Therapeutics News
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $2.14 and its highest was $11.88 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $103.03M.
When is Kalaris Therapeutics’s upcoming earnings report date?
Kalaris Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 57 days.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on May 12, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.523 by $0.063.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate is -0.5.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 23,792,278 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.523. Following the earnings report the stock price went up 1.268%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kalaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (149.21% Upside)
$15.75 (149.21% Upside)
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 4.0%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.99%
12-Months-Change
Fundamentals
Return on Equity
-72.78%
Trailing 12-Months
Asset Growth
6.51%
Trailing 12-Months
Company Description
Kalaris Therapeutics
Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.
KLRS Stock 12 Month Forecast
Average Price Target
$15.75
▲(149.21% Upside)
Technical Analysis
Coherus Biosciences
―
Nektar Therapeutics
―
Cellectis SA
―
Seres Therapeutics
―
Kodiak Sciences
―
Ownership Overview
54.44% Insiders
1.98% Mutual Funds
4.37% Other Institutional Investors
38.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---